Phase 2 KEYNOTE-002 trial in 540 patients with unresectable or metastatic melanoma who were refractory to prior ipilimumab and if BRAFv600 mutation positive, a BRAF inhibitor. The gene discussed is BRAF; the disease is metastatic melanoma.